What happened in this episode?
Alex Clark interviews Dr William Parker, author of Tylenol and Autism, who argues acetaminophen exposure in pregnancy, at labour and delivery, and in early childhood can contribute to autism in biologically susceptible children. Parker frames his view as a conclusion supported by “32 lines of evidence”, citing observational associations he attributes to studies during pregnancy and, more strongly, to a Johns Hopkins-linked analysis he says found higher acetaminophen at birth correlated with later autism diagnoses. He argues newborns have limited capacity to metabolise the drug safely and suggests risk is highest around birth and in the first months of life, while acknowledging uncertainty about whether single versus repeated doses drive harm.
Parker also attacks what he describes as the evidential basis for acetaminophen’s safety, saying historical research focused on liver outcomes with short follow-up and did not test neurodevelopment. The pair discuss policy options, including warning labels and removing infant formulations, while repeatedly noting they are not offering medical advice. Later, Parker alleges resistance within academic and clinical institutions, including claiming Duke University became hostile after his work gained attention and citing a Johnson & Johnson board link involving Duke leadership at the time.
In a separate set of claims, Parker suggests autism prevalence is rising sharply in lower socioeconomic groups and links this to cannabis exposure interacting with acetaminophen toxicity pathways, offering a contested “30%” estimate for Black boys in Los Angeles County and referencing NIH-related data he says show higher prevalence among Black boys than white boys.
